ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

ForteBio^®, a division of Pall Life Sciences (NYSE: PLL) and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read^™ Ni-NTA biosensor for use on its Octet^® and BLItz™ instrumentation platforms. The new biosensor is pre-immobilized with novel nickel-charged tri-nitrilotriacetic (Tri-NTA) groups enabling an easy, rapid and direct method for quantitation and kinetic analysis of polyhistidine-tagged (HIS-tagged) biomolecules.    

"Nickel provides an excellent binding medium for the stable capture of HIS-tagged proteins as part of quantitation and characterization studies," said Christopher Silva, ForteBio division's vice president of marketing. "However, standard formats for using this medium have been cumbersome, time-consuming and expensive. Now, our new Ni-NTA biosensor enables scientists to quickly and easily analyze HIS-fusion proteins with unsurpassed ease of use and workflow efficiency."

The Ni-NTA biosensor is designed for use in buffer and diluted complex media. Each biosensor can also be regenerated up to 10 times via a standard low-pH protocol in as little as two minutes for various applications such as acquisition of replicate data (same ligand/analyte pair) and "bucket-based" screening applications.

ForteBio's Octet family of products is based on the company's proprietary BioLayer Interferometry (BLI) technology. It incorporates disposable optical Dip and Read biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists in biotherapeutic discovery, process development and academic research.